Technology Advancements to Conquer the Precision Medicine Market

Wednesday, January 17, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

Chimeric Antigen Receptor (CAR) T Cell therapy prove effective in treating hematological cancers, with close to 90% clinical response rate


CLARA, Calif., Jan. 17, 2018 /PRNewswire/ -- Targeted and personalized therapeutics are likely to alter the existing precision medicine landscape. After the landmark US Food and Drug Administration (FDA) approval
of Novartis' CAR T-cell therapy, Kymriah, Frost & Sullivan finds that extensive work in CAR-T cells will fuel the development of transformative treatments. The FDA approval of Kymriah and other T-cell engaging antibody platforms will spur continued investment in, and development of, unique CAR T-cell therapy platforms across research and clinical settings.

Frost & Sullivan's analysis, Technologies Driving Precision Medicine, reveals that, in terms of technological challenges, CAR-T therapies will be expensive initially due to high production costs. However, the pricing may decrease with future technological advancements. In addition to price concerns, there is a challenge of managing of cytokine release syndrome, an adverse event related to T-cell therapies.

To access more information on this analysis, please visit:

"Cytokine release syndrome (CRS) is a life-threatening adverse event induced by CAR T-cell therapy, and it is one of the key setbacks impairing CAR T efficacy. However, with the recent US FDA approval of Roche's Actemra/RoActemra (tocilizumab) for CRS, there's new hope for the management of CAR T therapy induced CRS," said Vandana Iyer, TechVision Senior Research Analyst.

CAR-T therapies have proven effective against hematological cancers, with close to a 90% clinical response rate, including infants. Advances in enabling technological platforms will also continue to increase the efficacy of CAR T-cell therapies. For example, gene editing is allowing researchers to modify the CAR genes by knocking out proteins or other functions in the T-cells, which will help make the T-cells more resistant to immunosuppression. To drive further growth in the market, Frost & Sullivan determines that collaborations with biotech innovators and insurance providers will help accelerate product development and adoption.

"To address cost issues, companies should also develop strategic techniques that use cost-effective and scalable manufacturing platforms, which can help enhance savings on production costs, while also ensuring larger production volumes," said Iyer.

Technologies Driving Precision Medicine is part of Frost & Sullivan's global TechVision (Health & Wellness) Growth Partnership Service program.

About Frost & SullivanFrost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion

Technologies Driving Precision MedicineD7CB_TV

Contact:Mariana FernandezCorporate Communications – North AmericaP: +1 (210) 348 1012E:


Cision View original content:

SOURCE Frost & Sullivan

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store